{"id":4264,"date":"2026-11-12T09:00:00","date_gmt":"2026-11-12T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4264"},"modified":"2026-11-12T20:57:31","modified_gmt":"2026-11-13T00:57:31","slug":"fas88-design-improves-car-vdelta2-persistence-in-models","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4264","title":{"rendered":"Fas88 Design Improves CAR Vdelta2 Persistence in Models"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Leong_Lab_CAR_Vdelta2_Technology_and_Modalities-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4277\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Leong_Lab_CAR_Vdelta2_Technology_and_Modalities-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Leong_Lab_CAR_Vdelta2_Technology_and_Modalities-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Leong_Lab_CAR_Vdelta2_Technology_and_Modalities-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Leong_Lab_CAR_Vdelta2_Technology_and_Modalities-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Leong_Lab_CAR_Vdelta2_Technology_and_Modalities.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Leong Lab (academic)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Peer-reviewed publication (Nature Communications)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Gamma-delta CAR T with cytokine-armoring (Fas\u2013MyD88 fusion)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Fas88 CAR-V\u03b42 T cells<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>CD19; CD5; PSCA (models); Fas signaling<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Leukemia; T-ALL; pancreatic cancer (xenograft models)<\/p>\n<h4>Summary<\/h4>\n<p>A Nature Communications peer-reviewed paper appeared online November 12 describing Fas88, a Fas\u2013MyD88 fusion designed to turn activation-linked death signaling into IL-18-like survival signaling in CAR-V\u03b42 T cells. An April bioRxiv preprint preceded peer review; today\u2019s signal is journal publication.<\/p>\n<p>The investigators compared cytokine-armoring strategies and tested CAR-V\u03b42 cells in CD19 leukemia, CD5 T-ALL and PSCA pancreatic xenografts. Fas88 protected cells from Fas-mediated apoptosis and enhanced stimulus-dependent expansion and tumor control. These are preclinical xenograft findings, not human efficacy.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> one compact transgene may address both activation-induced cell death and cytokine support, improving an allogeneic gamma-delta cell platform. Support: mechanistic signaling and multiple in-vivo models. Against: immunodeficient mice cannot test host rejection or human cytokine toxicity.<\/p>\n<p><strong>Interpretation B:<\/strong> diversion of Fas apoptosis could produce unwanted persistence or transformation risk. Support: Fas is a normal control checkpoint and retroviral engineering adds insertional risk. Against: the authors observed contraction after stimulation. Clinical translation requires donor-to-donor manufacturing consistency, normal-tissue target testing, in-vivo trafficking, immunogenicity, replication-competent vector testing, genomic surveillance and a controllable safety switch. Failure to maintain benefit in immunocompetent models would narrow the platform thesis.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>V\u03b42 gamma-delta T cells are a potentially off-the-shelf immune-cell chassis. CARs redirect antigen recognition; Fas88 couples Fas extracellular sensing to MyD88 survival signaling, aiming to counter activation-induced cell death.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Verified: Nature-family online-first indexing and underlying experimental manuscript.<\/li>\n<li>Missing: clinical data, peer-reviewed full-text access in retrieval, independent replication, and safety-switch validation.<\/li>\n<li>The April preprint is identified separately from the November peer-reviewed date.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>Fas88 is a mechanistically notable attempt to solve cell persistence with one transgene. Human translation turns on controlled persistence, off-tumor activity, donor reproducibility and a safety mechanism.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: uncertain. Confidence in Facts: moderate-high. Confidence in Interpretation: moderate-low.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Nature Communications peer-reviewed paper appeared online November 12 describing Fas88, a Fas\u2013MyD88 fusion designed to turn activation-linked death signaling into IL-18-like survival signaling in CAR-V\u03b42 T cells. An April bioRxiv preprint preceded peer&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4277,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1462,1463,1461],"class_list":["post-4264","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-car-v2","tag-fas88","tag-leong-lab"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4264"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4264\/revisions"}],"predecessor-version":[{"id":4291,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4264\/revisions\/4291"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4277"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}